- Home
- DOUG vs ABOS Comparison
DOUG vs ABOS Comparison
Compare DOUG & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOUG
- ABOS
- Stock Information
- Founded
- DOUG 1911
- ABOS 1996
- Country
- DOUG United States
- ABOS United States
- Employees
- DOUG N/A
- ABOS N/A
- Industry
- DOUG Building operators
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- DOUG Real Estate
- ABOS Health Care
- Exchange
- DOUG Nasdaq
- ABOS Nasdaq
- Market Cap
- DOUG 142.2M
- ABOS 99.1M
- IPO Year
- DOUG N/A
- ABOS 2021
- Fundamental
- Price
- DOUG $1.58
- ABOS $1.56
- Analyst Decision
- DOUG
- ABOS Strong Buy
- Analyst Count
- DOUG 0
- ABOS 3
- Target Price
- DOUG N/A
- ABOS $9.33
- AVG Volume (30 Days)
- DOUG 1.0M
- ABOS 379.4K
- Earning Date
- DOUG 02-27-2025
- ABOS 11-12-2024
- Dividend Yield
- DOUG N/A
- ABOS N/A
- EPS Growth
- DOUG N/A
- ABOS N/A
- EPS
- DOUG N/A
- ABOS N/A
- Revenue
- DOUG $966,442,000.00
- ABOS N/A
- Revenue This Year
- DOUG $5.28
- ABOS N/A
- Revenue Next Year
- DOUG $16.40
- ABOS N/A
- P/E Ratio
- DOUG N/A
- ABOS N/A
- Revenue Growth
- DOUG 1.86
- ABOS N/A
- 52 Week Low
- DOUG $1.00
- ABOS $1.54
- 52 Week High
- DOUG $2.98
- ABOS $5.09
- Technical
- Relative Strength Index (RSI)
- DOUG 38.30
- ABOS 30.29
- Support Level
- DOUG $1.49
- ABOS $1.69
- Resistance Level
- DOUG $1.84
- ABOS $1.88
- Average True Range (ATR)
- DOUG 0.12
- ABOS 0.13
- MACD
- DOUG 0.00
- ABOS -0.00
- Stochastic Oscillator
- DOUG 25.79
- ABOS 4.88
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.